NewsRoom Articles - Page 102 of 224

MondayNov 21, 2022 10:30 am

Odyssey Health, Inc. (ODYY) Expands Executive Team of New Subsidiary in Strategic Move to Strengthen Marketing of Concussion, Neurological Therapies

Brain injuries affect all aspects of society, from recreational youth athletics to military trauma interventions Despite the commonality of brain concussion injuries — more than 5 million a year in the United States alone — no FDA-approved therapy exists Medical technology innovator Odyssey Health Inc. is working toward a commercialized product treatment solution to the unmet need of concussion injuries Odyssey’s product for treating brain concussion has recently completed a series of human and animal safety trials and is now being prepped for Phase II/III trials focused on proving efficacy The product administers neurosteroids across the blood-brain barrier to stop…

FridayNov 18, 2022 11:15 am

Cancer Care Adhering to Guidelines Could Help Reduce Treatment Disparities

Even though we have come a long way from the days of slavery, racial discrimination and disparities are still entrenched in American society. In many cases, racial biases prevent people of color from receiving high-quality medical care, with some studies showing that Black Americans are often undertreated for pain. Overall, the National Academy of Medicine has found that Black patients are much more likely to receive inferior care from their physicians compared to White patients. When it comes to serious medical conditions such as cancer, these disparities can have lifelong and even fatal consequences. Speaking at the annual Patient-Centered Oncology…

FridayNov 18, 2022 9:45 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Head of Technical R&D Presents Flagship NanoAbs Platform at Recent RAFT Conference

The presentation focused on BiondVax’s yeast fermentation system to manufacture innovative alpaca-derived recombinant nanosized VHH-antibodies (NanoAbs) and highlighted the company’s NanoAbs as a platform for development of therapeutics addressing diseases with large unmet medical needs and attractive commercial opportunities BiondVax’s lead NanoAb candidate, an inhaled COVID-19 treatment, exhibits significant competitive advantages over currently available mAbs and oral COVID-19 therapies Development of additional NanoAbs, targeting psoriasis, asthma, psoriatic arthritis and wet macular degeneration is underway via a strategic collaboration with the Max Planck Institute for Multidisciplinary Sciences and the University Medical Center Gottingen (“UMG”), both in Germany BiondVax Pharmaceuticals (NASDAQ: BVXV),…

ThursdayNov 17, 2022 1:34 pm

Surgical Team in Spain Completes First-Ever Intestinal Transplant

Organ transplants were a revolution in medicine that granted humanity even greater control over health and disease. The first organ to be transplanted successfully was a kidney in 1954, followed by the first liver, pancreas and heart transplants by the late 1960s; lung transplants followed in the 1980s. Organ transplants have become a crucial staple of medical care as they can significantly improve quality of life and prolong the lifespan of patients. Now, researchers in Spain have made medical history after they successfully implanted an intestine in a 13-month-old child. Little Emma was a victim of intestinal failure that had…

WednesdayNov 16, 2022 3:07 pm

Research Explains Why MS Patients Benefit from Stem Cell Transplants

Multiple sclerosis (MS) is a disorder where an individual’s immune system begins attacking the myelin, a protective sheath that protects the nerve fibers. In doing so, the communication signals between the brain and the rest of the body are impacted. An estimated 1 million U.S. citizens live with MS, with most of them receiving their diagnosis between the ages of 20 and 50. MS usually includes symptoms such as pain, permanent fatigue, paralysis, vision problems, muscle spasms and stiffness, and problems with cognitive functioning. Although there is currently no cure for multiple sclerosis, stem-cell treatments have proven to be quite…

WednesdayNov 16, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO Participated in The American Brain Tumor Association’s Breakthrough for Brain Tumors(R) 5K Run Following European Clinical Trial Site Activations

CNS Pharmaceuticals CEO John Climaco participated in 5K run on November 5, to show support for brain tumor patients worldwide and help raise funds for research The company recently announced European clinical trial site activations for its potentially pivotal global trial evaluating Berubicin for the treatment of recurring glioblastoma multiforme The pivotal trial will study Berubicin’s results compared to the current study of care, Lomustine Global brain tumor treatment market was valued at $2,946 million in 2022 and is expected to grow to $5,904 million by 2032 Brain and other central nervous system cancers (“CNS”) represent 1.3% of all new…

TuesdayNov 15, 2022 2:35 pm

Researchers Turn to AI for Insights on Treating Brain Tumors

With the fields of machine learning and artificial intelligence (AI) evolving almost daily, experts in several industries are trying to figure out ways the technology can advance their specific sectors. Artificial intelligence can analyze an unfathomable number of data points in shockingly little time and come up with conclusions that would have otherwise taken hundreds if not thousands of human work hours. In medicine, researchers hope this ability can help them treat two of the most difficult-to-treat diseases on the planet: brain and spinal tumors. Referred to as cavernous malformations, these are vascular tumors that develop in the spinal cord…

MondayNov 14, 2022 10:30 am

Odyssey Health, Inc. (ODYY) Focuses on Medical Devices Market with US Patent Application on Breath-Propelled Intranasal Delivery Device

Odyssey filed for US and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device that effectively deposits concentrated drug deep into the nasal cavity for the treatment of CNS injury disease or disorder The application follows the successful completion of the second Cohort of Odyssey’s Phase I MAD clinical trial, which saw the effective use of the device and a proven safety profile for the company’s concussion pharmaceutical treatment Michael Redmond, the company’s CEO, has expressed the company’s pleasure in the functionality of the device, citing how it provides a significant opportunity and advantage for the treatment of…

MondayNov 14, 2022 10:29 am

Scientists Look for Ways to Disable Sugar Molecule That Fuels Cancer Persistence

Even though there are several treatments that can be used to fight cancer and prolong a cancer patient’s life, the disease has no cure. For the longest time, scientists have been trying to find treatments that could completely eradicate cancer cells without the side effects typically associated with conventional cancer treatments, but no success has been registered. Recent research from the University of Basel has revealed that abnormal cancer cells specifically use sugar molecules on their surface to defend themselves against the immune system. According to University of Basel researchers, this mechanism can nullify this mechanism and make cancer cells…

MondayNov 14, 2022 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Focus on Advancing Clinical Development Program for Lead Drug Candidate, Berubicin

In June 2020, CNS’ lead drug candidate, Berubicin, received Orphan Drug designation from the FDA. In June 2021, it received Fast Track designation following positive results from an extensive clinical study that saw 44% of the patients post a clinical response, with one Durable Complete Response With GBM having a survival rate of only 6.8% and an average length of survival of only eight months, Berubicin is showing tremendous potential, and CNS is leading the charge to find a potential treatment option for the disease CNS’ management is optimistic about its lead drug candidate and continues to explore the potential…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Odyssey Health, Inc. (ODYY) Expands Executive Team of New Subsidiary in Strategic Move to Strengthen Marketing of Concussion, Neurological Therapies

Cancer Care Adhering to Guidelines Could Help Reduce Treatment Disparities

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Head of Technical R&D Presents Flagship NanoAbs Platform at Recent RAFT Conference

Surgical Team in Spain Completes First-Ever Intestinal Transplant

Research Explains Why MS Patients Benefit from Stem Cell Transplants

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO Participated in The American Brain Tumor Association’s Breakthrough for Brain Tumors(R) 5K Run Following European Clinical Trial Site Activations

Researchers Turn to AI for Insights on Treating Brain Tumors

Odyssey Health, Inc. (ODYY) Focuses on Medical Devices Market with US Patent Application on Breath-Propelled Intranasal Delivery Device

Scientists Look for Ways to Disable Sugar Molecule That Fuels Cancer Persistence

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Focus on Advancing Clinical Development Program for Lead Drug Candidate, Berubicin

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search